BioPhy

🌎 Incredible news: BioPhy has been named to Fast Company's World Changing Ideas List! We're honored to be recognized among organizations making a difference in the world. https://www.biophy.ai/wci #FCWorldChangingIdeas #AIdrugdevelopment #AIforgood

It is with profound sadness that we share the unexpected passing of our beloved co-founder and friend, Steven Truong, on March 6, 2025. Steve was not only a dynamic leader, he had a unique ability to approach every project and opportunity with boundless energy and enthusiasm. His dedication, kindness, and readiness to listen, truly defined him both as a colleague and as a friend. We want to honor Steve’s legacy and the remarkable contributions he made to our company. His pride in what we built together will continue to inspire us every day, as we carry on the work the BioPhy family has been so proud to deliver. Steve leaves behind his loving wife, Julie, and two young children, whose strength and resilience will undoubtedly continue to inspire all who knew him. In remembrance of his life and to celebrate the profound impact he had on us all, we invite all who knew him to pay tribute and support one another during this difficult time. Rest in peace, Steve. You will be deeply missed, and your spirit will forever remain a part of BioPhy, and all those who knew you.

Check out The Pharmaverse Podcast! Thank you for inviting Dave Latshaw II, PhD, MBA to kick-off 2025 on The Pharmaverse Podcast. BioPhy is very grateful to have him share the exciting future of AI in Drug Development! Dave Latshaw II, PhD, MBA; Michael Pietrack #AIinPharma #AIforgood #AIdrugdevelopment

BioPhy would like to wish everyone a Happy Holiday season!  2024 has been a year of tremendous progress and growth for us, and this would not have been possible without the tireless contributions of the BioPhy team, feedback from our customers, and the trust of our investors.  We look forward to building on this momentum in 2025 and continuing our mission of providing practical AI for drug development!

RAPS San Francisco Chapter is excited to kick off 2025 by featuring Peter Marks, M.D., Ph.D. from the FDA as the speaker at our first in-person event on January 12th in downtown San Francisco. Dr. Marks will be providing his thoughts and insights on what to expect from the FDA in the new year. We do expect the event to fully sell out, so please take advantage of Early Bird pricing that is valid for the next month until 12/14. Registration link is here: https://lnkd.in/g9vszmmc Thank you to our Gold Sponsors SGS and BioPhy, Silver Sponsor IPM Integrated Project Management Company and Qserve Group, Bronze Sponsor MyData-TRUST - Data Protection & Privacy for Life Sciences and Weave. #RAPS #regulatoryaffairs #FDA

Wonderful feature in STAT! Always feels good to be on the leading edge.

🚀 Exciting Feature in STAT! 🚀 While AI-driven drug discovery might take years to reach the market, the immediate impact on clinical trial efficiency could speed up the path to approval for existing drug candidates. This is a game changer in our pursuit of more effective treatments for diseases ranging from cancer to rare conditions and beyond. It’s always rewarding to be on the cutting edge of innovation, and this feature in STAT highlights just how transformative AI is becoming in the world of clinical trials. Forward-thinking companies are harnessing the power of machine learning and artificial intelligence to streamline the design and execution of clinical trials. From improving trial protocols to optimizing patient recruitment and monitoring, AI is helping pharma accelerate the development of life-changing treatments. At BioPhy, we are proud to be part of this exciting frontier, leveraging advanced AI technologies to help transform how clinical trials are conducted. We're committed to using innovative tools to make drug development faster, smarter, and more precise. Looking forward to what the future holds as we continue to push the boundaries of what's possible with AI in healthcare! 🌟 BioPhy’s modular platform is designed to allow us to meet pharma companies and our clients anywhere in their AI adoption journey to help them meet and exceed their goals. Katie Palmer 🙏 grateful for including BioPhy https://lnkd.in/e_Ar_crG #AI #MachineLearning #ClinicalTrials #PharmaInnovation #DrugDevelopment #BioPhy #HealthTech #Pharma #Platform #AIforGood

How Generative AI Will Find a Place in the Pharma Industry Now and in the Years to Come Great article on MedCity News about the role of generative AI in the pharmaceutical industry. Dave Latshaw II, PhD, MBA emphasizes that “generative AI will not only accelerate the drug development process but also enhance our understanding of complex diseases.” This technology is poised to transform how we approach drug development, making it more efficient and precise. At BioPhy, we’re excited to leverage these advancements to drive innovation in healthcare! Check out the full article here: https://lnkd.in/gsXcRfcG #Pharma #DrugDevelopment #AI #Innovation #Biotechnology #AIforGood

Overcoming Pharma’s Major Pain Points and Pitfalls With AI A growing share of capital in the discovery space is now directed towards artificial intelligence, poised to revolutionize how we identify and optimize biological modules. As this technology continues to accelerate discovery processes, companies must prepare for increased productivity. However, expanding capabilities brings challenges—namely, the limited availability of skilled professionals and the high costs of recruitment. While AI is driving efficiency, its true potential lies in tackling some of pharma’s biggest bottlenecks: 1️⃣ Costly Clinical Trials: AI can shorten trial durations, optimize resources, and predict outcomes—cutting costs and speeding up drug development. 2️⃣ Delayed Commercialization: Transitioning molecules from discovery to approval involves many moving parts. AI enhances workflows across regulatory, quality, and clinical operations, ensuring smoother transitions and faster paths to market. 3️⃣ Limited Lifecycles: AI can uncover new therapeutic uses for existing drugs, maximizing a product’s impact and commercial viability. By adopting AI, we’re entering a new era of faster, cost-effective drug development and broader therapeutic applications, ultimately bringing life-saving treatments to patients more quickly. The future is bright for both pharma and patients alike. For more information see this Op-ed in MedCity News by our CEO Dave Latshaw II, PhD, MBA, BioPhy https://lnkd.in/g-Vtx_VN #AI #Pharma #DrugDevelopment #Innovation #Healthcare #AIforgood